DK1630173T3 - Fremgangsmåde til udvinding af biologisk aktivt humant G-CSF fra inclusion bodies - Google Patents

Fremgangsmåde til udvinding af biologisk aktivt humant G-CSF fra inclusion bodies

Info

Publication number
DK1630173T3
DK1630173T3 DK05107881.4T DK05107881T DK1630173T3 DK 1630173 T3 DK1630173 T3 DK 1630173T3 DK 05107881 T DK05107881 T DK 05107881T DK 1630173 T3 DK1630173 T3 DK 1630173T3
Authority
DK
Denmark
Prior art keywords
csf
biologically active
inclusion bodies
active human
extraction
Prior art date
Application number
DK05107881.4T
Other languages
English (en)
Inventor
Arndt Dietrich
Bernhard Janowski
Joerg Schaeffner
Ulrich Kurt Blaschke
Original Assignee
Bioceuticals Arzneimittel Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35406424&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1630173(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bioceuticals Arzneimittel Ag filed Critical Bioceuticals Arzneimittel Ag
Application granted granted Critical
Publication of DK1630173T3 publication Critical patent/DK1630173T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Steroid Compounds (AREA)
DK05107881.4T 2004-08-27 2005-08-29 Fremgangsmåde til udvinding af biologisk aktivt humant G-CSF fra inclusion bodies DK1630173T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004041639A DE102004041639A1 (de) 2004-08-27 2004-08-27 Verfahren zur Gewinnung von biologisch aktivem humanen G-CSF aus Inclusion Bodies

Publications (1)

Publication Number Publication Date
DK1630173T3 true DK1630173T3 (da) 2010-03-15

Family

ID=35406424

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05107881.4T DK1630173T3 (da) 2004-08-27 2005-08-29 Fremgangsmåde til udvinding af biologisk aktivt humant G-CSF fra inclusion bodies

Country Status (10)

Country Link
EP (1) EP1630173B1 (da)
AT (1) ATE447584T1 (da)
CY (1) CY1109754T1 (da)
DE (2) DE102004041639A1 (da)
DK (1) DK1630173T3 (da)
ES (1) ES2336007T3 (da)
HR (1) HRP20100053T1 (da)
PL (1) PL1630173T3 (da)
PT (1) PT1630173E (da)
SI (1) SI1630173T1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005033250A1 (de) * 2005-07-15 2007-01-18 Bioceuticals Arzneimittel Ag Verfahren zur Reinigung von G-CSF
GB0605684D0 (en) * 2006-03-21 2006-05-03 Sicor Biotech Uab Method For Purifying Granulocyte-Colony Stimulating Factor
WO2008096370A2 (en) * 2007-02-05 2008-08-14 Natco Pharma Limited An efficient and novel purification method of recombinant hg-csf
EP2445924B2 (en) 2009-06-25 2023-12-13 Amgen Inc. Capture purification processes for proteins expressed in a non-mammalian system
WO2011113601A1 (en) * 2010-03-17 2011-09-22 Biogenerix Ag Method for obtaining biologically active recombinant human g-csf
CN101830977B (zh) * 2010-05-07 2012-01-25 厦门特宝生物工程股份有限公司 一种重组人粒细胞刺激因子的纯化方法
HUP1200172A2 (en) 2012-03-19 2013-10-28 Richter Gedeon Nyrt Methods for refolding g-csf from inclusion bodies
HUP1200171A1 (hu) 2012-03-19 2013-09-30 Richter Gedeon Nyrt Módszerek polipeptidek elõállítására
US9982012B2 (en) 2013-03-29 2018-05-29 Dr. Reddy's Laboratories Limited Refolding of granulocyte colony stimulating factor
WO2019175633A1 (en) * 2018-03-15 2019-09-19 Petiva Private Limited Methods for refolding sucrose isomerase

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL86090A (en) * 1987-04-16 1993-03-15 Cetus Oncology Corp Production of purified, biologically active, bacterially produced recombinant human csf-1
DE4014750A1 (de) 1990-05-08 1991-11-14 Boehringer Mannheim Gmbh Muteine des granulozyten-stimulierenden faktors (g-csf)
WO1993003134A1 (en) * 1991-07-29 1993-02-18 Immunex Corporation Process for isolating and purifying recombinant interleukin-7
IL152804A0 (en) * 2000-05-16 2003-06-24 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
GB0019375D0 (en) * 2000-08-07 2000-09-27 Int Centre Genetic Eng & Bio Method of polypeptide renaturation
US20040116663A1 (en) * 2001-01-16 2004-06-17 Soren Buus Method for refolding of proteins
JPWO2005033307A1 (ja) * 2003-09-30 2006-12-14 技術研究組合 生物分子工学研究所 新規のリフォールディング方法およびその方法によって得られたタンパク質

Also Published As

Publication number Publication date
CY1109754T1 (el) 2014-09-10
EP1630173B1 (de) 2009-11-04
EP1630173A2 (de) 2006-03-01
HRP20100053T1 (hr) 2010-03-31
SI1630173T1 (sl) 2010-03-31
PT1630173E (pt) 2010-02-12
EP1630173A3 (de) 2006-03-08
DE102004041639A1 (de) 2006-03-02
DE502005008432D1 (de) 2009-12-17
ATE447584T1 (de) 2009-11-15
PL1630173T3 (pl) 2010-04-30
ES2336007T3 (es) 2010-04-07

Similar Documents

Publication Publication Date Title
DK1630173T3 (da) Fremgangsmåde til udvinding af biologisk aktivt humant G-CSF fra inclusion bodies
CY1112323T1 (el) Παραγωγη και καθαρισμος της il-29
SG162834A1 (en) Refolding of recombinant proteins
EA200702487A1 (ru) Пегилированные соединения glp-1
BRPI0618488A2 (pt) proteìnas de fusão de ìntron de fator de crescimento de hepatócito
JP2011173911A5 (da)
WO2007110231A3 (en) MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES
PE20120777A1 (es) Combinacion de un inhibidor de nucleosido polimerasa con un inhibidor de proteasa macrociclica y su uso en el tratamiento de hepatitis c, fibrosis hepatica y funcion hepatica alterada
EA201591766A1 (ru) Мутеины интерлейкина-2 для экспансии регуляторных т-клеток
BRPI0510654A (pt) formulações de interferon em hidrogel
NO20065860L (no) Stabiliserte flytende interferonformuleringer
DE602005026931D1 (de) Verwendung von vorstufen von enkephalinen und/oder deren fragmenten in der medizinischen diagnostik
UY28731A1 (es) Compuestos quimicos
NO20071591L (no) Interleukin-9 og interleukin-4 kimaere antagonist muteiner og fremgangsmater for anvendelse derav.
RU2008136191A (ru) Лечение рака мочевого пузыря с использованием ео9 и пропиленгликоля
Miller et al. Novel approaches for long-term lung transplant survival
WO2006014864A3 (en) Methods and compositions for reducing c-reactive protein
ATE411038T1 (de) S100 protein als aktivator neutrophiler zellen zur verminderung der neutropenie bei der krebsbehandlung
BRPI0416434A (pt) métodos para aumentar a atividade de uma proteìna de ácido esfingomielinase (asm), para estender a meia-vida e prolongar a atividade de uma proteìna asm purificada, para aumentar a produção de uma proteìna asm recombinante através de uma célula hospedeira, e usos de uma composição de asm tipo alelo-selvagem, purificada e um composto análogo de ceramida ou esfingomielina, e de um composto análogo de ceramida ou de esfingomielina
WO2010123699A3 (en) Compositions, kits and methods for promoting ischemic and diabetic wound healing
DE60236109D1 (de) Klasse-ii-cytokinrezeptoren und deren verwendungen
UA108779C2 (uk) Композиція та спосіб лікування раку
BRPI0407266A (pt) Composição de droga citostática
ATE516306T1 (de) Verbessertes verfahren zur reinigung von tfpi und tfpi-analogen
AR053284A1 (es) Terapia genica de interferon -beta usando un sistema mejorado de expresion regulada